Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Short-term Investments (2020 - 2025)

Tango Therapeutics has reported Short-term Investments over the past 6 years, most recently at $400000.0 for Q4 2025.

  • Quarterly results put Short-term Investments at $400000.0 for Q4 2025, down 99.79% from a year ago — trailing twelve months through Dec 2025 was $400000.0 (down 99.79% YoY), and the annual figure for FY2025 was $400000.0, down 99.79%.
  • Short-term Investments for Q4 2025 was $400000.0 at Tango Therapeutics, down from $94.5 million in the prior quarter.
  • Over the last five years, Short-term Investments for TNGX hit a ceiling of $350.0 million in Q1 2022 and a floor of $400000.0 in Q4 2025.
  • Median Short-term Investments over the past 5 years was $47.7 million (2023), compared with a mean of $128.8 million.
  • Biggest five-year swings in Short-term Investments: soared 31505.72% in 2024 and later plummeted 99.85% in 2025.
  • Tango Therapeutics' Short-term Investments stood at $567000.0 in 2021, then changed by 0.0% to $567000.0 in 2022, then surged by 58.73% to $900000.0 in 2023, then surged by 20831.89% to $188.4 million in 2024, then tumbled by 99.79% to $400000.0 in 2025.
  • The last three reported values for Short-term Investments were $400000.0 (Q4 2025), $94.5 million (Q3 2025), and $428000.0 (Q2 2025) per Business Quant data.